RxDoctor Payments Data

Daniel Ramirez, MD

Vascular Surgery · Miami, FLNPI 1134160781

Payments from drug & device makers

$6,127in general payments, 2019–2025

Across 97 payments — averaging $63.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • W. L. Gore & Associates, Inc.$2K
  • Silk Road Medical, Inc.$648
  • Shockwave Medical, Inc$613
  • Bard Peripheral Vascular, Inc.$531
  • Penumbra, Inc.$514
  • Getinge USA Sales, LLC$254
  • plus $2K from 22 others

What the payments were for

  • Travel & lodging$1,64227%
  • Food & beverage$4,48573%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,127 in reported general payments places this provider in the 45th percentile of 385 vascular surgery providers in Florida.

See all vascular surgery providers in Florida

Medicare billing

Part B allowed, 2024
$35,011
Medicare patients
41
Services billed
142

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban47$38,409
XareltoRivaroxaban11$7,212
ClopidogrelClopidogrel Bisulfate140$846
Gabapentin110$561
Cilostazol46$475
Atorvastatin Calcium65$303
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen50$201
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim23$77
Tramadol Hcl13$56
Ropinirole Hcl12$51
Metformin Hcl11$48
Meloxicam13$17
Alprazolam32$13

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$75$7,21211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 385 vascular surgery providers in Florida.

Other vascular surgery in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →